: The binding affinities of 12 different neurotransmitter receptors were measured using a radio-labeled receptor assay.
Cerebral cortex of male Wistar rat (200-250g) was used. The method of homogenation was the same procedure described in the paragraph of dopamine 1 receptor and dopamine 2 receptor.
F. Histamine 1 (H1) receptor Brain stem of male Wistar rat (200-250g) was used. The method of homogenation was the same procedure described in the paragraph of dopamine 1 receptor and dopamine 2 receptor. Iv. The analysis of results of the binding assays The dissociation constant (Kd) and maximal number of binding sites (Bmax) were determined by Scatchard plots of data from the saturation experiments for each receptor. The affinity constant (Ki) of each antipsychotic drug was obtained from the inhibition curve of the displacement experiment data, i.e, Ki values were calculated as follows : Ki = IC50/(1+ C/ Kd), where IC50 is the concentration that 50% inhibits A. DA receptors (1) D1 receptors The affinity of the following drugs for D1 receptors (i.e., the ability to block D1 receptors) was high (Ki on the order of 1nM) : fluphenazine, perphenazine, levomepromazine, and chlorpromazine. The Ki of these drugs for D, receptors ranged between 2.5nM and 6.3nM. Moderate affinity (Ki on the order of lOnM) was recorded for propericiazine, clocapramine, clotiapine, zotepine, carpipramine, oxypertine, and mosapramine. Relatively low affinity (Ki on the order by sulpiride and oxypertine. (4) D4 receptors High affinity for D4 receptors was shown by timiperone, haloperidol, bromperidol, nemonapride, and clotiapine. Moderate affinity was shown by SM -9018 , clocapramine, pimozide, zotepine, thioridazine, chlorpromazine, levomepromazine, and propericiazine. Relatively low affinity was shown by masapramine, fluphenazine, carpiramine, perphenazine, and oxypertine. Low affinity was shown by sulpiride and sultopride, i.e., by all benzamides tested except nemonapride.
B . 5HT receptors
(1) 5HT1A receptors As a whole affinity for 5HT1A receptors tended to be low. High affinity was shown by SM-9018. None of the antipsychotic agents currently on the market showed high affinity for this receptor. Moderate affinity was shown by nemonapride. Relatively low affinity was shown by zotepine, oxypertine, pimozide, timiperone, etc. All benzamides except nemonapride had low affinity (Ki over 1ƒÊM).
(2) 5HT2 receptors As a whole affinity for 5HT2 receptors tended to be high.
Levomepromazine, SM-9018, clocapramine, carpi- Ki values were calculated by using the formula : IC50/(1.+C/Kd), where IC50 is the concentration of the drug that half maximaly displaces the 3H-ligand, C is the concentration of 3H-ligand, and Kd is its dissociation constant.
The data printed in boldface could not be found in any report except ours. showed that the therapeutic doses of antipsychotic agents were inversely correlated with their ability to bind to DA receptors. Since then, blockade of DA receptors has been considered a major mechanism of antipsychotic actions.
As a result of recent advances in pharmacology and molecular biology studies, it has been found that DA receptors can be divided into five subtypes. These five subtypes are grouped into two families on the basis of their pharmacologic profiles : the D1 family (D1 and D5) and the D2 family (D2, D3 and D4). The present study dealt with D1, D2, D3 and D4.
(1) D1 family D1 receptors are distributed in the corpus striatum , the substantia nigra, the limbic system, and the ventral tegmental area. Behavioral pharmacology studies have shown that simultaneous stimulation of D1 and D2 receptors results in stereotyped behavior25'26). Oral dyskinesia has also been reported when D1 receptors were blocked after blocking D2 receptors27). These findings suggest that blockade of D1 receptors is also involved in antipsychotic actions.
In the present study, high affinity for D1 receptors (Ki on the order of 1nM) was shown by phenothiazines such as fluphenazine, perphenazine, levomepromazine, and chlorpromazine. The affinity of butyrophenones for D1 receptors was lower (Ki on the order of 100nM). Data concerning anti-D1 action have been reported by Hyttel et al.28 ) and Kinoshita29). The IC5o reported for antipsychotic agents by Hyttel et al. was about 10 times lower than that obtained in the present study. This discrepancy is probably due to the difference in ligands used in the two studies. Consistent with previous reports, the anti-D, receptor activity of phenothiazines tended to be higher than that of butyrophenones in the present study. No reports prior to the present study have dealt with the affinity of levomepromazine, propericiazine, clothiapine, zotepine, timiperone, carpipramine, oxypertine, or sultopride for D1 receptors.
(2) D2 family The same as D1 receptors, D2 receptors are dis- Anti-5HT2 activity dominant drugs were divided two groups.
We recommend the following guidelines for selecting drugs ; When the patient has severe hallucinations and/or delusions, drugs belonging to anti-D2 activity dominant groups should be used . When the patient shows negative symptoms, drugs belonging to anti-5HT2 activity dominant groups should be used . D3 receptors are mainly distributed in the limbic system. They serve as the autoreceptors of DA neurons") and are involved in mental functions such as cognition and emotion.30) The anti-D3 receptor activity of chlorpromazine, thioridazine, and clotiapine is higher than their anti-D2 receptor activity. Anti-D3 receptor activity has also been reported by Tada et al11). and Sokoloff et al. 30 . The data obtained in the present study was similar to their data. No reports prior to the present study have dealt with the affinity of levomepromazine, propericiazine, perphenazine, clotiapine, zotepine, timiperone, carpipramine,oxypertine, or sultopride for D3 receptors.
D4 receptors are distributed in the cerebral cortex and the limbic system. Clozapine has been shown to be useful in the treatment of chronic schizophrenia characterized by negative symptoms (e.g., avolition, affective flattening, and social withdrawal) and treatment-resistant schizophrenia, and to block D4 receptors12). On the basis of such findings, a relationship between anti-D4 receptor activity and successful treatment of negative symptoms was hypothesized. In recent years, however, it has been reported that only a small number of D4 receptors are present in the brain32'33). Thus, the validity of the this hypothesis has not yet been confirmed. In the present study, butyrophenones and SM-9018 (an atypical antipsychotic agent) were found to have relatively high anti-D4 receptor activity. The data obtained in the present study concerning the potency of anti-D, receptor activity of antipsychotic agents was similar to that reported by Van Tol et al12). No reports prior to the present study have dealt with the affinity of levomepromazine, propericiazine, perphenazine, clotiapine, timiperone, carpipramine, oxypertine, or sultopride for D4 receptors. B 5HT receptors 5HT has been reported to be involved in mood disorders and symptoms of schizophrenia such as anxiety, depression, obsession, and aggressiveness34). At present, 7 families (14 subtypes) of 5HT receptor are known. The present study dealt with 5HT1A, 5HT2, and 5HT3 receptors.
5HT1A receptors are distributed in the limbic systern, the raphe nuclei and the hippocampus. They are involved in body temperature and blood pressure regulation, eating behavior, anxiety, and aggressiveness35). In the present study, the affinity of all antipsychotic agents for 5HT1A receptors was on the 100nM order. Affinity for 5HT1A receptors was low with all agents except SM-9018 and nemonapride. Nishizaki36) and Zolan et al. 37 ) have reported the affinity of antipsychotic agents for this type of receptor. The data obtained in the present study were similar to the data in their report. No reports prior to the present study have dealt with the affinity of levomepromazine, propericiazine, perphenazine, fluphenazine, clotiapine, timiperone, pimozide, carpipramine,clocapramine, oxpertine or sultopride for 5HT1A receptors. Tandospirone has recently been used clinically as a nonbenzodiazepine anxiolytics. This drug is said to serve as a 5HT1A agonist and to suppress 5HT neurons via the autoreceptor 5HT,A38,39). In the present study, the Ki for this receptor was lower (i.e., the affinity for this receptor was greater) with SM-9018 and nemonapride than with tandospirone (Ki = 92nM5)). SM-9018 has not yet been introduced clinically and no detailed data on this drug is available. Nemonapride is known to have antianxiety activity") and seems to act as a 5HT1A agonist, the same as tandospirone. 
II. Clinical applications
The same as behavioral-pharmacology experiments, the performance of receptor binding experiments is a routine procedure in the process of developing of psychotropic agents. A great deal of data have been accumulated in receptor binding experiments. In Japan, however, few reports of receptor binding experiments carried out on currently used drugs under the same experimental conditions have been published. In other countries, a number of reports of such experiments involving antipsychotic agents have been published, but many of these experiments have not involved any drugs used in Japan. With this in mind, we performed receptor binding experiments on many drugs used in Japan under identical experimental conditions. Although the present study did not examine all types of receptors identified, the data obtained in this study will be clinically useful in assessments of the major efffects of antipsychotic agents. Clinical application of the data obtained will be discussed in terms of the three aspects below.
A. Classification of antipsychotic agents The classification shown in Table 3 overlaps the classification based on chemical structures, except for fluphenazine. This classification will be useful in the following clinical settings.
(1) When selecting drugs according to the stage of the disease 1) Acute stage Major symptoms seen in this stage are positive symptoms such as hallucinations and delusions. Drugs with high affinity for D2 receptors should be selected to suppress these symptoms. Drugs belonging to the three anti-DA receptor activity dominant groups (Group A through Group C) are recommended. These include haloparidol, bromperidol, fluphenazine, timiperone, and pimozide.
2) Chronic stage Major symptoms in this stage are negative symptoms such as avolition and affective flattening. Drugs with high affinity for 5HT2 receptors should be selected to suppress these symptoms. Drugs belonging to Group D (one of anti-5HT receptor activity dominant groups) are recommended. These include carpipramine, chlorpromazine, levomepromazine, clotiapine, propericiazine, perphenazine and thioridazine.
3) Subacute to subchronic stage (mixed stage) Hallucinations and delusions have subsided, and anxiety, hypochondriasis, and depressed mood are the major symptoms in this stage. Drugs with high affinity for D2 and 5HT2 receptors should be selected to suppress these symptoms. Drugs belonging to Group E (one of anti-5HT receptor activity dominant groups) are recommended. These include mosapramine, clocapramine, zotepine, and oxypertine.
(2) When selecting combined drug therapy It seems rational to select drugs from different groups for combined therapy. Drugs belonging to the same group have similar pharmacologic profiles, and combined use of these drugs will have no effect other than to increase the dose level of the drug initially used.
(3) When using a combination of drugs with the same affinity profile as unapproved drug. The affinity profile of a given drug can be reproduced by combining two or more other drugs having similar profiles. For example, the profile of an unapproved drug can be reproduced by combining approved drugs with similar profiles. In fact, we have succeeded in treating some cases by using a cocktail of drugs whose profile resembles that of olanzapine7). This method will become more widely applicable when data concerning antidepressants etc5), as well as antipsychotic agents, are included.
B. Drug therapy based on the concept of SDA for the treatment of chronic or intractable cases of schizophrenia in which negative symptoms predominate Pharmacologic studies of risperidone (an atypical antipsychotic drug) have revealed a clinical phenomenon in which negative mental symptoms are reduced by strong blockade of 5HT2 receptors. This finding led to proposal of the concept of serotonin-dopamine antagonists (SDA)55). Matsubara et al.56) used the ratio of the affinity for 5HT2 to affinity for D2 receptors (pKi) to distinguish typical antipsychotic agents from atypical antipsychotic agents (pKi > 1.2). If the data obtained in the present study are used, the 5HT2/D2 ratio is less than 1 for the butyrophenones (haloperidol, bromperidol, timiperone) and fluphenazine, and greater than 1.2 for levomepromazine, thioridazine, propericiazine, and clotiapine (Table 4) . Although the present study did not involve any atypical antipsychotic agents, the drugs mentioned above can be regarded as SDAs defined by Matsubara et al.56). The 5HT2/D2 ratio of antidepressants5) also ranged between 0.8 and 1.5, as we reported elsewhere. It can therefore be concluded that antidepressants as well as the drugs in Group D may be useful in treating cases with negative symptoms.
C . Side effects of antipsychotic agents The type and dose level of drugs, the background variables of the patient (age, sex), and other factors are known to be associated with the onset of extrapyramidal symptoms (EPS). This paper will summarize the potency of individual antipsychotic agents in inducing EPS. EPS is thought to involve not only the balance between anti-DA and anti-Ach actions, but anti-5HT
actions. This view is based on the report that DA transmission in the nigrostriatal pathway is improved by blockade of 5HT2 receptors and stimulation of 5HT1A receptors.
It has not yet been fully clarified how antipsychotic agents act on 5HT1A receptors, and thus this summary will include D2, Ach, and 5HT2 receptors, but exclude 5HT1, receptors. Fig.2 shows the total affinity for 5HT2 and Ach receptors of drugs that suppresses EPS (positive, i.e., upward part) and the affinity for D2 receptors that induces EPS (negative or downward part) in graph form. The downward part is marked for fluphenazine, timiperone, haloperidol, bromperidol, and benzamides. These drugs are likely to cause EPS and need to be carefully used in clinical cases. Phenothiazines usually show high affinity for 5HT2 and Ach receptors and suppress EPS. However, only fluphenazine in this family seems likely to cause EPS, because its affinity for 5HT2 is lower than for D2 receptors. This is corroborated by the clinical report of an EPS incidence close to 50% among patients treated with fluphenazine57). Fig.2 suggests that butyrophenones are likely to induce EPS, but the incidence of EPS in clinical cases was not high (between 10% and 50%). This discrepancy is probably attributable to some other factors such as dose level. EPS are the most important adverse reaction that needs so be borne in mind when using antipsychotic agents. To avoid this adverse reactions, it is recommended that Fig.2 
